Cargando…

Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19

Schizophrenia spectrum disorders (SSD) are complex mental disorders, and while treatment with antipsychotics is important, many patients do not respond or develop serious side effects. Genetic variation has been shown to play a considerable role in determining an individual’s response to antipsychot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandhu, Amrit K., Naderi, Elnaz, Wijninga, Morenika J., Liemburg, Edith J., Cath, Danielle, Bruggeman, Richard, Alizadeh, Behrooz Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532576/ https://www.ncbi.nlm.nih.gov/pubmed/37763122 http://dx.doi.org/10.3390/jpm13091354

Ejemplares similares

The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis
por: Teng, Yuxin, et al.
Publicado: (2023)

Deep Clinical Phenotyping of Schizophrenia Spectrum Disorders Using Data-Driven Methods: Marching towards Precision Psychiatry
por: Habtewold, Tesfa Dejenie, et al.
Publicado: (2023)

Six-year trajectories and associated factors of positive and negative symptoms in schizophrenia patients, siblings, and controls: Genetic Risk and Outcome of Psychosis (GROUP) study
por: Habtewold, Tesfa Dejenie, et al.
Publicado: (2023)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits
por: Habtewold, Tesfa Dejenie, et al.
Publicado: (2020)

Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics
por: Cacabelos, Ramón, et al.
Publicado: (2012)

Pharmacogenetic Expression of CYP2C19 in a Pediatric Population
por: Pierre-François, Marie Josette Déborah, et al.
Publicado: (2022)

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
por: Fohner, Alison E., et al.
Publicado: (2020)

Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations
por: Ford, Graeme R., et al.
Publicado: (2022)

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
por: de la Torre, Rafael, et al.
Publicado: (2012)

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes
por: Stingl, Julia Carolin, et al.
Publicado: (2022)

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
por: El Rouby, Nihal, et al.
Publicado: (2018)

6. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes
por: van Schaik, Ron H.N.
Publicado: (2008)

A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, and VKORC1 Genes
por: Tron, Camille, et al.
Publicado: (2022)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine
por: Lee, Su-Jun
Publicado: (2013)

In Silico Pharmacogenetics CYP2D6 Study Focused on the Pharmacovigilance of Herbal Antidepressants
por: Don, Charleen G., et al.
Publicado: (2020)

Understanding Lifelong Factors and Prediction Models of Social Functioning After Psychosis Onset Using the Large-Scale GROUP Cohort Study
por: Tiles-Sar, Natalia, et al.
Publicado: (2023)

Distribution of CYP2B6 516G/T pharmacogenetically important polymorphism in the Ukrainian population
por: Filiptsova, Olga, et al.
Publicado: (2018)

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
por: Nizamuddin, Sheikh, et al.
Publicado: (2021)

Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug
por: Li, Qian, et al.
Publicado: (2021)

Pharmacogenetic testing revisited: 5′ nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19
por: Larsen, Jens Borggaard, et al.
Publicado: (2017)

The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia
por: Rodrigues-Silva, Christielly, et al.
Publicado: (2020)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsy
por: Jose, Manna, et al.
Publicado: (2014)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
por: Caudle, Kelly E., et al.
Publicado: (2019)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
por: Bojić, Mirza, et al.
Publicado: (2019)

Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Carvalho Henriques, Beatriz, et al.
Publicado: (2021)

Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation
por: Kalra, Kapil, et al.
Publicado: (2009)

Pharmacogenetics of CYP3A5 on Carbamazepine pharmacokinetics in epileptic patients developing toxicity
por: Al-Gahtany, Mubarak, et al.
Publicado: (2014)

Copy number variation profiling in pharmacogenetics CYP-450 and GST genes in Colombian population
por: Ramírez, Brian, et al.
Publicado: (2019)

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
por: Mukonzo, Jackson K., et al.
Publicado: (2014)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

Design and implementation of a novel pharmacogenetic assay for the identification of the CYP2D6*10 genetic variant
por: Ranadeva, Nadeeka Dimuthu Kumari, et al.
Publicado: (2022)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

Correction: Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Henriques, Beatriz Carvalho, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cj3uj7cquf6qetd4egne8a3ns0